REGN Regeneron Pharmaceuticals Loading...

Loading chart...
Top Calls
Feed
All Sources✓
YouTube✓
Twitter✓
Reddit✓
Substack✓
Insider✓
Loading...
0 selected
All Content✓
Source feeds
Buzzberg's Top 50 ✓
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
23:29
May 23
seedy19tron Biotech trader, L/S
The tweet references Rezpeg (likely REGN's pipeline candidate) with data across thousands of patients and multiple indications, but lacks a forward-looking directional view or trade call.
REGN
HIGH
12:56
May 08
A May MD Biotech investor
Adam May argues Nektar Therapeutics' bold Phase 3 strategy for Rezpeg in atopic dermatitis, including a biologic-refractory trial no pharma giant has run, could drive over $5B in peak sales and make NKTR a glaring M&A candidate at current prices.
REGN
HIGH
00:04
Apr 26
TraderStewie Founder, Art of Trading
Traderstewie shares a list of upcoming earnings from Earnings Whispers for the week of April 27, 2026, but
REGN
HIGH
23:44
Apr 09
Jim Cramer Host, Mad Money CNBC
Cramer said Regeneron is "breaking out here," with CEO Leonard Schleifer doing an unbelievable job, and he likes the stock for its pipeline and earnings growth. Company has rising earnings, a strong product pipeline, and positive momentum, making it appealing for investment. Technical breakout and fundamental strength support a LONG position. Pipeline setbacks or regulatory challenges could hinder growth.
REGN 1ST

About REGN Analyst Coverage

Buzzberg tracks REGN (Regeneron Pharmaceuticals) across 4 sources. 1 bullish vs 0 bearish calls from 4 analysts. Sentiment: predominantly bullish (25%). 4 total trade ideas tracked.